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Abstract
Objective: Lithium users are offered routine renal monitoring but few studies have quantified the risk to renal health. The
aim of this study was to assess the association between use of lithium carbonate and incidence of renal failure in patients
with bipolar disorder.
Methods: This was a retrospective cohort study using the General Practice Research Database (GPRD) and a nested
validation study of lithium exposure and renal failure. A cohort of 6360 participants aged over 18 years had a first recorded
diagnosis of bipolar disorder between January 1, 1990 and December 31, 2007. Data were examined from electronic primary
care records from 418 general practices across the UK. The primary outcome was the hazard ratio for renal failure in
participants exposed to lithium carbonate as compared with non-users of lithium, adjusting for age, gender, co-morbidities,
and poly-pharmacy.
Results: Ever use of lithium was associated with a hazard ratio for renal failure of 2.5 (95% confidence interval 1.6 to 4.0)
adjusted for known renal risk factors. Absolute risk was age dependent, with patients of 50 years or older at particular risk of
renal failure: Number Needed to Harm (NNH) was 44 (21 to 150).
Conclusions: Lithium is associated with an increased risk of renal failure, particularly among the older age group. The
absolute risk of renal failure associated with lithium use remains small.
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Introduction
Lithium carbonate has been a cornerstone of treatment of
bipolar disorder for more than 40 years and more recently a key
augmentive treatment for unipolar depression. Its narrow thera-
peutic window and potential for lethal toxicity [1] has led to an
increasing use of alternative agents, particularly valproate. The
effect of lithium on the kidney influences prescribing decisions, and
monitoring of renal function is part of standard care. Uncertainty
remains about the level of renal harm associated with lithium use
for bipolar treatment, as well as the role of duration of exposure
[2]. Its known effect on tubular function (resulting in nephrogenic
diabetes insipidus) has been contrasted with a less well-established
association with renal failure, possibly confounded by other known
risk factors [3]. Reported epidemiological studies are either cross-
sectional, small cohort [4–12], or small case-control [13–19]. Of
the case-control studies none were adequately powered to analyse
the effect of age or concomitant drugs [13–19]. A recent systematic
review [20] demonstrated that the evidence base for renal
monitoring for patients taking lithium is surprisingly weak. No
large-scale study has been conducted with adequate power to
detect renal failure outcomes in lithium use, adjusted for other risk
factors. However, lithium prescribing remains widespread, with
evidence of anti-suicidal effects [21], [22] and a clear role within
clinical guidelines for bipolar disorder [23], [24].
Because of the availability of a large, UK-representative study
population, we were able to estimate the incidence of renal
outcomes in the General Practice Research Database (GPRD,
http://www.gprd.com/) cohort during the period 1990–2007 in
patients with bipolar disorder according to age, gender, and use of
lithium. This study estimates the relative hazard of renal failure
(the primary outcome) and renal impairment (the secondary
outcome) in patients with bipolar disorder according to lithium use
and adjusted for age, gender, known risk factors for renal disease
and lithium exposure over time. The GPRD has been extensively
validated to record primary care prescriptions; an unknown
proportion of lithium prescribing may originate from secondary
care, thus the study also sought to validate GPRD renal failure,
ever-use of lithium and lithium exposure records.
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Methods
Ethics Statement
Data was accessed within limits set out by the Medical Research
Council licence agreement for academic access with Medical
Research Ethics Committee ethical approval. The proposal was
approved by the Independent Scientific Advisory Committee of
the GPRD (protocol number 07_107R).
Data Source
A retrospective cohort study was conducted, accessing records
from the GPRD, which provided anonymised access to electronic
primary care medical records and prescriptions for approximately
6% of the UK population. The age and sex distribution of the
GPRD population was similar to the general population and each
contributing GP practice was audited monthly to ensure data
quality. The database contained information on consultation
dates, diagnosis, symptoms, procedures or investigation, referrals,
their outcome, drug frequency and dose. Diagnoses and prescrip-
tions were recorded using OXMIS and Prescription Pricing
Authority (PPA) codes respectively; all codes for bipolar disorder,
renal outcomes, medications and all covariates are available on
request from the corresponding author. Data were accessed from
the GPRD under the MRC licence for academic groups [25].
Disease Definitions
Renal disease occurring in patients was defined using two
definitions capturing severity and spectrum of disease. The
primary outcome, renal failure (RF), included diagnostic and
referral codes indicating end stage renal failure, chronic kidney
disease stages 4 or 5 (CKD4 and CKD5) and renal replacement
therapy (dialysis or transplantation). The secondary outcome,
renal impairment (RI) included diagnostic codes for milder degrees
of renal dysfunction including chronic kidney disease stage 3
(CKD3). Disease definitions were developed under the supervision
of a consultant nephrologist (JM).
Study Population
Patients were identified for inclusion on the basis of diagnosis of
bipolar disorder recorded in the medical record. General practices
were selected that provided quality-checked data from 1st January
1990–31st December 2007, including 2,130,070 patients regis-
tered with these practices aged 18 years or over. Patients with less
than one year of GP registration were excluded, as were patients
with renal cancer, congenital abnormalities or renal conditions
relating to pregnancy. Male and female patients were identified
with a first recorded occurrence of bipolar disorder after 1 January
1990.
Patient records were examined for first and subsequent
prescriptions of lithium. In addition to renal outcomes, patient
records were evaluated for diagnoses of diabetes mellitus,
cardiovascular disease, cerebrovascular disease, liver disorder,
other diseases of the urinary system (renal sclerosis, small kidney);
prescriptions for nonsteroidal anti-inflammatory drugs (NSAIDs),
paracetamol, angiotensin-converting enzyme (ACE) inhibitors,
diuretics, b-adrenoceptor-blocking drugs and other antihyperten-
sives, antipsychotics (quetiapine, risperidone, or olanzapine), and
mood stabilizing drugs (sodium valproate, lamotrigine, or
carbamazapine). Reflecting variable reporting, smoking and
alcohol status were crudely categorized by ‘‘never’’ or ‘‘ever’’
usage. Mean BMI was calculated using all BMI readings within
the study window and categorized as underweight (,18.5), normal
(18.5 to 24.9), overweight (25 to 29.9), obese (30 to 39.9), morbidly
obese (.40). GP practices were allocated a quintile score for
socioeconomic status based in the Index of Multiple Deprivation
(IMD) [26].
Drug Exposure Definitions
Lithium use incorporated the following proprietary and generic
classifications: Camcolit, Liskonum, Priadel, Li-Liquid, lithium
carbonate and lithium citrate. A pre-specified definition of lithium
exposure duration adjusted using the Defined Daily Dose method
[27] was planned, but following a validation exercise (see below
and results), dose-adjusted exposure duration was not included in
the analyses presented.
Exposure to NSAIDs was categorized as non-use, #30 days
(short-term use) and .30 days (long-term use). Cardiovascular
dose aspirin was excluded from NSAID categorisation. Other
drugs recorded and available to statistical models included b-
adrenoreceptor blocking drugs, diuretics, ace inhibiting drugs,
antipsychotics (quetiapine, risperidone, or olanzapine), and mood
stabilizing drugs (sodium valproate, lamotrigine, or carbamaza-
pine). Exposure was defined as at least one prescription record in
the time window following bipolar diagnosis and before a renal
outcome (if occurring).
Validation
A validation exercise was conducted with permission from
GPRD which aimed to examine (i) the primary outcome of renal
failure, (ii) ever-use of lithium in those with a record of renal
failure, and (iii) lithium exposure duration in those with a record of
renal failure. We requested access to the full text of general
practice records covering the duration within the cohort for each
case. Validation was conducted by sending a questionnaire to
registered GPs asking for confirmation and additional details of
renal failure (and bipolar disorder) diagnosis, lithium exposure,
date of birth and gender. Copies of confirmatory patient notes
were requested.
Analysis
The relative risks of renal outcomes (RI and RF) were estimated
as hazard ratios (HRs) for lithium use compared to non-use, using
Cox proportional hazard models. Models were subsequently
adjusted for patient demographics, comorbidity and concomitant
drug use. These included baseline variables (recorded at the time
of diagnosis of bipolar disorder), and emergent variables (recorded
following diagnosis of bipolar disorder but before diagnosis of a
renal outcome) putatively related to renal disease.
We carried out both forward and backward stepwise covariate
selection within the Cox proportional hazard model. All covariates
(age, gender, alcohol use, smoking, BMI, GP practice Index of
Multiple Deprivation (IMD), cerebrovascular disease, cardiovas-
cular disease, liver failure, diabetes, malignancy, hypertension,
atypical antipsychotics, mood stabilizers, beta-blockers, diuretics,
ace-inhibitors, paracetamol, NSAIDS) were initially included with
entry testing based on the significance of the score statistic, and
removal testing based on the probability of a likelihood-ratio
statistic based on conditional parameter estimates. Final selected
models were re-estimated to provide unconditional estimates. Data
management was generally performed using Stata 10IC [28] and
the Cox regression proportional hazard computations [29] and
Kaplan-Meier survival analysis used SPSS [30]. Final models were
tested for (and rejected) time-dependency and interactions
between fitted variables. Precision of estimates is reported using
95% confidence intervals.
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Results
Baseline Cohort Characteristics
The cohort consisted of 6360 patients within 418 practices with
a first diagnosis of bipolar disorder recorded from 1st January
1990 to 31st December 2007 (figure 1). The cohort mean age at
diagnosis was 48.8 years (range 18 to 105), 60.5% were women
and median follow-up was 5.4 years (3 months –18 years, SD 4.6
years). A total of 22% of patients had ten or more years of follow-
up. All cause mortality during follow-up was 773 (12.2%). BMI,
smoking status and alcohol use were inconsistently recorded
(records in 54.9%, 93.3% and 84.3% respectively) and status
varied over time. The socio-economic status (SES) of practices was
evenly spread across the cohort from least to most deprived, with
no clinically important differences in lithium prescribing rates.
Emergent Cohort Characteristics
Within the cohort, following diagnosis of bipolar disorder but
before any diagnosis of renal disease a range of emergent
conditions were diagnosed (Table 1). Most variables were not
associated with renal disease within regression models, or only
fitted in univariate analysis. A number of these variables were
correlated: diabetes, hypertension and use of diuretics, beta-
blockers and ACE inhibitors and thus not independently
explanatory.
Lithium Exposure
A total of 2496 patients (39% of the cohort) were prescribed at
least one prescription of at least 30 days duration for lithium. The
mean age of commencing lithium therapy was 49.8 years (SD
16 y, range 17–97 y). Lithium users were recruited at a similar
rate to non-lithium users over the period. Users and non-users of
lithium had clinically similar baseline demographic characteristics
(Table 1), although small differences appear statistically significant
in this large cohort. Lithium users were slightly older than non-
lithium users at recruitment (49.8 vs. 48.1 years), and had longer
mean duration of follow-up (7.4 vs. 5.7 years).
Renal Outcomes
During cohort follow-up, there were 77 cases of incident renal
failure (RF) and 375 incident cases of renal impairment (RI). The
unadjusted prevalence of RF (2.0% vs. 0.7%) and RI (10.2% vs.
3.1%) was higher in lithium users than non-users (Table 2).
Adjusted for age and gender, ever-use of lithium was associated
with an increased risk of developing renal failure (HR: 2.5 (95%
confidence interval 1.6 to 4.0)) and renal impairment (HR: 2.7 (2.2
to 3.4)). Several predictor variables showed a very weak but
significant bivariate correlation with renal failure but did not fit in
fully adjusted models, namely: ACE-inhibitors (Pearson correla-
tion coefficient r = 0.082, p,0.001), beta-blockers (Pearson corre-
lation coefficient r = 0.041, p = 0.001), hypertension (Pearson
Figure 1. Flowchart of study participants.
doi:10.1371/journal.pone.0090169.g001
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correlation coefficient r = 0.053, p = 0.001), and paracetamol
(Pearson correlation coefficient r = 0.049, p = 0.001). The follow-
ing covariates did not show a bivariate correlation with renal
failure; age, gender, alcohol use, smoking, BMI, GP practice Index
of Multiple Deprivation (IMD), cerebrovascular disease, cardio-
vascular disease, liver failure, malignancy, atypical antipsychotics
and mood stabilizers.
Fully adjusted multivariable analysis including the influence of
covariates on renal failure is shown in Table 3. All covariates were
initially included in the model, and final adjusted models
demonstrated an association between renal failure and lithium
use (HR: 2.7 (95% CI 1.7 to 4.3), diuretic use (HR: 2.3 (1.4 to 3.7),
and diabetes (HR: 2.8 (1.6 to 4.6). Although diuretics showed a
statistically significant association, hypertension as a stand-alone
variable did not fit either model. Gender did not have a significant
effect in any of the final adjusted model, nor did several traditional
renal risk factors such as smoking and alcohol use. Long term
NSAID use ($30 days) was weakly associated with renal failure
(HR 1.5 (0.7 to 3.2)) but was not statistically significant. The final
models are consistent with age and gender adjusted models
Table 1. Cohort baseline and emergent characteristics at diagnosis of bipolar disorder, according to use or nonuse of lithium.
Total N=6360 (%) Lithium Users N=2496 (%) Non-Users N=3864 (%) P5
Age (y) 18 to 34 1482 (23) 473 (19) 1009 (26)
35 to 49 1983 (31) 811 (33) 1172 (30)
50 to 64 1626 (26) 703 (28) 923 (24)
65 to 79 960 (15) 402 (16) 558 (14)
80+ 309 (4.9) 107 (4.3) 202 (5.2)
Mean (SD) 48.8 (17) 49.8 (16) 48.1 (18) ,0.001
Gender Male 2511 (40) 995 (40) 1516 (39) 0.59
Female 3849 (61) 1501 (60) 2348 (61)
Alcohol user1 4470 (83)2 1846 (85) 2624 (82) 0.001
Smoker1 3649 (61)3 1430 (60) 2219 (62) 0.16
BMI1 Underweight 78. (2.2) 23 (1.5) 55 (2.8)
Normal 1094 (31) 472 (31) 622 (32)
Overweight 1202 (34) 533 (35) 669 (34)
Obese 990 (28) 439 (29) 551 (28)
Morbidly Obese 127 (3.6)4 62 (4.1) 65 (3.4)
Mean (SD) 28. (6.3) 28 (6.1) 27.9 (6.4) ,0.001
Practice IMD6 0 1272 (20) 506 (20) 766 (20) 0.07
1 1005 (16) 430 (17) 575 (15)
2 1229 (20) 495 (20) 734 (19)
3 1385 (22) 485 (20) 900 (23)
4 1469 (23) 580 (23) 889 (23)
Comorbidity (any) 1410 (22) 549 (22) 861 (22) 0.76
Cerebrovascular Disease 286 (4.5) 76 (3.0) 210 (5.4) ,0.001
Cardiovascular Disease 765 (12) 282 (11) 483 (13) 0.16
Liver Failure 14 (0.2) 5 (0.2) 9 (0.2) 0.79
Diabetes 492 (7.7) 205 (8.2) 286 (7.4) 0.25
Malignancy 197 (3.1) 93 (3.7) 104 (2.7) 0.02
Hypertension 638 (10) 276 (11) 326 (8.4) 0.001
Atypical antipsychotics 1977 (31) 868 (35) 1109 (29) ,0.001
Mood stabilizers 1656 (26) 670 (27) 986 (26) 0.28
Beta-blockers 912 (14) 434 (17) 478 (12) ,0.001
Diuretics 1192 (19) 452 (18) 740 (20) 0.28
Ace-inhibitors 645 (10) 253 (10) 392 (10) 0.94
Paracetamol 2648 (42) 1218 (49) 1430 (37) ,0.001
NSAIDS. Long-term (.30d) 202 (3.2) 76 (3.0) 126 (3.3%) 0.001
1Earliest recorded value following diagnosis, as a proportion of those in whom status is recorded.
215.7% of patients had missing data.
36.1% of patients had missing data.
445.1% of patients had missing data.
5p-values: comparison of binary variables by adjusted x2 test; continuous variables by Student’s t-test; multiple category variables by x2 test adjusted for trend.
6Index of Multiple Deprivation (IMD) based on practice post-code. 0 is least deprived, 4 is most deprived.
doi:10.1371/journal.pone.0090169.t001
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(Table 2). Given the effect of age on the models, data were
partitioned into younger (18 to 49 years) and older (50+ years)
cohorts and the model (fully adjusted, validated model shown in
table 3) was re-evaluated. Although there was no interaction
between age and lithium use within regression models in this
study, increasing risk of renal failure with age meant that the
absolute risk associated with lithium use in older patients was
notable (Figure 2).
Model Specification
Reported models were tested for and rejected time dependency
of covariates or interactions between variables in most instances.
There were no instances of interaction between lithium use and
other covariates. The findings for lithium are not confounded by
age; reported models are adjusted by age as a continuous variable,
but regression analyses using age as a categorical variable also
show lithium exposure as an independent risk factor for renal
failure.
Cessation of Lithium and Persistence of Increased Risk
We examined whether lithium exposure was associated with a
persistently increased risk of renal failure. Fifty-one lithium users
developed renal failure during the evaluation period, and at least
35 of these renal failure events occurred during lithium treatment
or within 6 months of cessation. The validation study (reported
below) indicated an underestimation of lithium exposure duration;
thus more refined exposure analyses were deemed unreliable and
are not reported here.
Full Text Validation Exercise and Sensitivity Analysis
Of 77 cases of renal failure, 44 (57%) records were available for
extraction and analysis. Of the remainder, 3 died, 11 had changed
to a different IT system preventing identification using the GPRD
unique identifier, 4 patients had transferred out of the area with no
notes available, 2 patients were with practices that no longer
wished to participate in GPRD studies, and there were13 non-
responses. Of the 44 patients whose records were analysed, all 28
patients previously identified as lithium users were confirmed.
Lithium exposure duration was confirmed in all but 6 patients; of
these, duration had potentially been under-estimated by between
4–32 years (mean 12.3 y, SD 10.3 y). There was insufficient
information to assess whether exposure during these periods was
continuous or interval. In the 16 patients previously identified as
non-users of lithium, note review showed that 2 had evidence of
lithium use in letters from secondary care (duration unknown). A
sensitivity analysis was conducted taking into account the
misclassified cases, with almost identical results.
Of the 44 patients whose records were analysed (and who were
previously identified as having renal failure), we were able to
confirm 33 (75%) cases of renal failure, of whom 3 had a record of
dialysis. An additional 4 patients had a record of chronic kidney
stage 3, and 3 had a record of renal impairment with stage
unknown. Of the 33 confirmed cases of renal failure, the date of
onset was available for 23 (70%); of these, 17 (74%) were within 30
days of the previously identified date, and the remainder of cases
were within 1 year. A sensitivity analysis was conducted excluding
un-validated cases of renal failure, again with almost identical
results (Table 3 shows results from both unvalidated and validated
data).
Clinical Importance
Underlying risk of renal disease increases with age, consequently
risk of harm was estimated for younger (,50 years) and older ($50
years) cohorts of patients undergoing treatment. In patients under
50 years of age using lithium, the estimated absolute increase in
risk of renal failure was 0.15% (number needed to harm, NNH:
Table 2. Unadjusted and adjusted hazard ratios for renal failure and renal impairment among lithium users and non-users.
n/N (%) HR (95%CI), p Unadjusted HR (95%CI), p Age and sex-adjusted
Renal Failure 77/6360 (1.2)
Lithium use (unvalidated) 49/2494 (2.0) 2.1 (1.3 to 3.4), 0.002 2.2 (1.4 to 3.6), 0.001
Non-use 28/3866 (0.7)
Lithium use (validated) 51/2496 (2.0) 2.4 (1.5 to 3.8), ,0.001 2.5 (1.6 to 4.0), ,0.001
Non-use 26/3864 (0.7)
Renal Impairment 375/6360 (5.9)
Lithium use 255/2494 (10.2) 2.5 (2.0 to 3.1), ,0.001 2.7 (2.2 to 3.4), ,0.001
Non-use 120/3866 (3.1)
doi:10.1371/journal.pone.0090169.t002
Figure 2. Renal failure survival curves for younger and older
lithium and non-lithium users.
doi:10.1371/journal.pone.0090169.g002
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660, 95%CI: 300 to 2100) and renal impairment was 0.95%
(NNH: 105, 95%CI: 69 to 167). In patients over 50 years of age
using lithium, the estimated increase in risk of renal failure was
2.3% (NNH: 44, 95%CI: 21 to 150) and renal impairment was
8.0% (NNH: 13, 95%CI: 8 to 20).
Discussion
This retrospective cohort enquiry provides evidence for the
strength of association linking lithium use with renal disease [31].
The linkage is further enhanced by consistency across renal
outcome definitions (failure and impairment) and by insensitivity
to adjustment for potential confounding variables. Lithium use was
associated with a two and a half-fold increased risk in renal failure
and nearly a three-fold increased risk of renal impairment. Our
study confirms lithium’s role as an independent risk factor for renal
failure, which increases with age.
The biological mechanism for renal impairment and renal
failure in long-term lithium treatment remains to be fully
elucidated [20], [32]. Although early biopsy studies found a range
of renal pathologies in those exposed to lithium, these were not
clearly linked to reduced glomerular function. More recent studies
report a more consistent picture of tubulointerstitial disease in long
term lithium users who develop renal impairment [33], with focal
segmental glomerulosclerosis or multiple microcysts detectable by
magnetic resonance imaging [34], which is likely to be due to a
specific effect of lithium rather than the result of established
common risk factors for renal failure [35]. It remains unknown
whether specific risk factors exist which increase vulnerability to
lithium-associated renal failure, and hence whether a high-risk
group can be identified at the outset of treatment. There may be
genetic factors, but a causal role for either acute or chronic lithium
toxicity remains a plausible but untested hypothesis. It was not
possible within the current study to explore the role of acute
lithium poisoning which may have led to renal failure in this
population. It remains uncertain to what extent renal damage
occurs as a result of high serum lithium levels as opposed to
individual susceptibility even at normal therapeutic serum levels of
lithium. A recent systematic review [20] demonstrates that the
majority of studies inconsistently report daily doses and duration of
use, concurrent diabetes insipidus or acute renal injury, concom-
itant drug use, and exclude patients with acute lithium toxicity,
thus the role of these risk factors remains uncertain. This study was
unable to address these issues, and thus interpretation of findings is
limited by the unknown influence of variations in dose, duration,
toxicity, and interactions with other drugs.
Diagnostic criteria for the index diagnosis, bipolar disorder,
have changed over time and GPs use different classifications for a
variety of reasons, consequently psychiatry colleagues within the
team developed a wide-ranging code list to ensure that we
captured a wide cohort of patients with a diagnosis of bipolar
disorder. The mean age of the cohort was slightly older than that
reported in other studies of patients with bipolar disorder [36]; it is
possible that GPRD may not record bipolar diagnosis until some
years after a diagnosis is made in secondary care. It is also possible
that patients treated with lithium represent more severe bipolar
disorder and thus the findings may result from selection bias.
However, findings show little difference between the lithium-
exposed and non-exposed groups for a range of emergent disease
parameters. It may be that the lithium-exposed group have more
severe bipolar disorder, but they do not appear to have more
severe physical disorders.
Cases of renal failure were selected using a highly specific code
list, but the definition of renal impairment was wider; until recently
(with the introduction of Quality Outcome Frameworks (QOF) in
primary care [37]) GPs in England were not required to record the
level of severity of renal disease. Possible inconsistencies in GP
data entry using diagnostic codes may have led to an overestima-
tion of the prevalence of renal impairment but underestimation of
renal failure. Our validation study demonstrates reliable recording
of renal failure and supports previous validation research [38].
However, it is notable that although the validated code list had
high specificity, its sensitivity remains unknown and follow-up
studies using laboratory confirmed renal failure (for example
eGFR) are needed to confirm findings.
Previous research [22] identifies diabetes and hypertension as
independent risk factors for renal disease. Within our study,
diabetes and anti-hypertensive diuretic drug use were significantly
associated with renal failure. However, in fully adjusted models,
hypertension itself not associated with renal disease although this
may be a result of historical GPRD data entry inconsistencies.
NSAID use has also been shown in previous research [22] to be an
independent explanatory variable for renal failure. In this study,
long term NSAID was weakly associated with renal failure but was
not statistically significant.
Prescriptions for lithium issued in secondary care, for example,
in specialist psychiatric and nephrology clinics may not be
recorded in the GPRD. Thus exposure to lithium may be
underestimated in these patients. Our first reported validation
study of lithium exposure supported GPRD dataset classification
of exposure per se, but led us to conclude that lithium exposure
duration determined using the GPRD dataset alone was unreli-
able, due to evidence of secondary care prescribing. Although
most long-term prescribing for stable patients is likely to occur in
primary care, drug therapy at onset or during crises may be
managed by the secondary care psychiatrist. This is an example of
‘immeasurable time bias’, a recognized bias in pharmacoepide-
miology studies resulting from missed exposure missed in
observational databases due to hospital admission or outpatient
secondary care [39]. It is possible that lithium use may be
withdrawn due to development of renal impairment, while those
on long-term lithium use may demonstrate a ‘healthy survivor’
effect. Patients exposed to lithium may have been offered more
intensive screening, thus the study may be limited by ascertain-
Table 3. Final adjusted hazard ratios for renal failure among lithium and non-lithium users (using validated data).
Unvalidated data HR (95% CI), p Validated data HR (95% CI), p
Age 1.04 (1.03 to 1.06), ,0.001 1.04 (1.03 to 1.06), ,0.001
Lithium user 2.4 (1.5 to 3.8), ,0.001 2.7 (1.7 to 4.3), 0.001
Diuretic 2.3 (1.4 to 3.7), 0.001 2.3 (1.4 to 3.7), 0.001
Diabetes 2.8 (1.6 to 4.6), ,0.001 2.7 (1.6 to 4.5), ,0.001
doi:10.1371/journal.pone.0090169.t003
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ment bias in that the unexposed group may have undetected renal
disease. This may be more likely to occur in renal impairment.
However, our primary outcome of renal failure represents more
advanced disease, which will be less susceptible to this ascertain-
ment bias.
Despite inevitable limitations of the retrospective cohort design
this study provides consistent evidence of the link between lithium
use and renal disease. In absolute terms there is a small increased
risk of renal disease with lithium use. However this increases with
age, with numbers needed to harm (NNH) for renal failure of 44 in
patients aged 50 and over. There is a need for rigorous, routine
renal monitoring from the onset of treatment, and for patients to
be informed of this risk when deciding to use lithium therapy for
bipolar disorder. The risks need to be balanced against the
evidence for lithium’s comparative effectiveness in this group.
Comprehensive examination of potentially important co-factors
such as lithium exposure duration and lithium toxicity demand
prospective studies in this and other diagnostic groups.
Data Availability
GPRD Read code lists are available on request from h.j.close@
durham.ac.uk.
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